Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Radiolabeled oligonucleotides for antisense imaging.

Iyer AK, He J.

Curr Org Synth. 2011 Aug 1;8(4):604-614.

2.

Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.

Fu P, Shen B, Zhao C, Tian G.

J Nucl Med. 2010 Nov;51(11):1805-12. doi: 10.2967/jnumed.110.077982. Epub 2010 Oct 18.

3.
4.

Antisense imaging: and miles to go before we sleep?

Lewis MR, Jia F.

J Cell Biochem. 2003 Oct 15;90(3):464-72. Review.

PMID:
14523980
5.
6.

Radiolabelled oligonucleotides for imaging of gene expression with PET.

Lendvai G, Estrada S, Bergström M.

Curr Med Chem. 2009;16(33):4445-61. Review.

PMID:
19835563
7.

Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide.

Touboul M, Gauchez AS, D'Hardemare Adu M, Lunardi J, Deverre JR, Pernin C, Mathieu JP, Vuillez JP, Fagret D.

Anticancer Res. 2002 Nov-Dec;22(6A):3349-56.

PMID:
12530086
8.

Noninvasive imaging of human telomerase reverse transcriptase (hTERT) messenger RNA with 99mTc-radiolabeled antisense probes in malignant tumors.

Liu M, Wang RF, Zhang CL, Yan P, Yu MM, Di LJ, Liu HJ, Guo FQ.

J Nucl Med. 2007 Dec;48(12):2028-36. Epub 2007 Nov 15.

9.

In vitro characterization of two novel biodegradable vectors for the delivery of radiolabeled antisense oligonucleotides.

von Guggenberg E, Shahhosseini S, Koslowsky I, Lavasanifar A, Murray D, Mercer J.

Cancer Biother Radiopharm. 2010 Dec;25(6):723-31. doi: 10.1089/cbr.2010.0813.

PMID:
21204767
11.

[Prerequisites for diagnostic use of antisense oligonucleotides in nuclear medicine].

Hildebrandt M, Reske SN.

Nuklearmedizin. 1996 Aug;35(4):126-31. Review. German.

PMID:
9005406
12.

Antisense radiotherapy: targeting full-size mdrl mRNA with 125I-labelled oligonucleotides.

Gaidamakova EK, Neumann RD, Panyutin IG.

Int J Radiat Biol. 2004 Nov-Dec;80(11-12):889-93.

PMID:
15764398
13.
14.

Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.

White PJ, Anastasopoulos F, Pouton CW, Boyd BJ.

Expert Rev Mol Med. 2009 Mar 23;11:e10. doi: 10.1017/S1462399409001021. Review.

PMID:
19302730
15.

Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.

Oberbauer R.

Wien Klin Wochenschr. 1997 Jan 31;109(2):40-6. Review.

PMID:
9123943
16.
17.

A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.

Hussain M, Shchepinov M, Sohail M, Benter IF, Hollins AJ, Southern EM, Akhtar S.

J Control Release. 2004 Sep 14;99(1):139-55.

PMID:
15342187
18.

Potential use of radiolabeled antisense oligonucleotides in oncology.

Gauchez AS, Du Moulinet D'Hardemare A, Lunardi J, Vuillez JP, Fagret D.

Anticancer Res. 1999 Nov-Dec;19(6B):4989-97. Review.

PMID:
10697501
19.

Antisense oligonucleotides for cancer therapy-an overview.

Stahel RA, Zangemeister-Wittke U.

Lung Cancer. 2003 Aug;41 Suppl 1:S81-8. Review.

PMID:
12867066
20.

Antisense oligonucleotides as therapeutics for malignant diseases.

Ho PT, Parkinson DR.

Semin Oncol. 1997 Apr;24(2):187-202. Review.

PMID:
9129689

Supplemental Content

Support Center